CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma

BACKGROUND: Histone deacetylase inhibitors (HDACIs) have distinctive epigenetic targets involved in hepatocarcinogenesis and chemoresistance. A recent phase I/II study reported the possibility of HDACI as a chemosensitizer in sorafenib-resistant patients. In this study, we evaluated whether CKD-5, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Young, Lee, Yun Bin, Cho, Eun Ju, Lee, Jeong-Hoon, Yu, Su Jong, Kim, Yoon Jun, Yoon, Jung-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559883/
https://www.ncbi.nlm.nih.gov/pubmed/33059615
http://dx.doi.org/10.1186/s12885-020-07471-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559883/
https://www.ncbi.nlm.nih.gov/pubmed/33059615
http://dx.doi.org/10.1186/s12885-020-07471-3

Ejemplares similares